tbuckley/cabot-search huggingface dataset:
Abstract NT-112: APTAMER CONJUGATED NANOPARTICLES FOR TARGETED DRUG DELIVERY
Authors: Varatharasa Thiviyanathan, Fengmei Pi, Hui Zhang, Hui Li, Hongyu Wang, Peixuan Guo, Anil Sood
Journal: Clinical Cancer Research (2019)

Abstract Targeted Delivery of therapeutic drugs and imaging agents, using nanoparticles, shows great promise in diverse fields, including the diagnostics and treatment of cancer. Monoclonal antibodies (mAbs) that have been traditionally used for detecting specific proteins can also be used as targeting moieties. However, due to their intrinsic characteristics such as immunogenicity, batch-to-batch variation and instability, antibodies have several limitations for in vivo applications. Nucleic acid based aptamers are emerging as attractive alternatives for mAbs. We have developed single-stranded DNA aptamers, which can specifically recognize and bind to ovarian cancer endothelial cells. Using mass-spectroscopy based proteomics, we have identified Annexin A2 as the protein target for the selected aptamers. These aptamers can act as homing devices to deliver therapeutic drugs and/or imaging agents specifically to ovarian cancer cells. Using a highly stable, three-way junction (3WJ) motif from the phi29 packaging RNA as a scaffold, we made a multi-functional RNA nanoparticle that can harbor therapeutic drugs, imaging agent, siRNA and the targeting ligand. The aptamer-containing multi-functional RNA nanoparticle is used to deliver Doxorubicin to Annexin A2 positive ovarian cancer cells, while the control nanoparticles failed to deliver. After systemic injection in mice, the DNA/RNA hybrid nanoparticles remained intact and strongly bound to tumors with little accumulation in healthy organs 6 hour post-injection. The aptamer-3WJ-Sph1/Dox intercalates selectively enhanced toxicity to Annexin A2 positive ovarian cancer cells in vitro, demonstrating the potential of the constructed DNA/RNA hybrid nanoparticles to enhance the therapeutic efficiency of Doxorubicin at low doses for ovarian cancer treatment. The use of the aptamer-3WJ RNA nanoparticle will benefit ovarian cancer patients by reducing the side effects of cancer chemo-therapeutics and increasing its local concentration in the tumor microenvironment after systemic administration. Our ultimate goal is the development of patient-optimized aptamer-nanoparticle delivery systems for chemotherapy and molecular diagnostics imaging. Citation Format: Varatharasa Thiviyanathan, Fengmei Pi, Hui Zhang, Hui Li , Hongyu Wang, Peixuan Guo, Anil Sood. APTAMER CONJUGATED NANOPARTICLES FOR TARGETED DRUG DELIVERY [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr NT-112.
Untangling the Effects of Chemotherapy and HIV on CD4 Counts—Implications for Immunotherapy in HIV and Cancer
Authors: Rachel Bender Ignacio, Henry Ddungu, Thomas S. Uldrick
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer.
Authors: Roberto Angioli, Francesco Plotti, Corrado Terranova, Michela Angelucci, Irma Oronzi, Roberto Montera, Patrizio Damiani, Ester Valentina Cafà , Federica Guzzo, Eva Montone, Roberto Ricciardi, Alessia Aloisi, Entela Hyseni, Daniela Luvero, Giuseppe Scaletta, Stella Capriglione, Salvatore Lopez, Andrea Miranda, Marta Li Destri, Pierluigi Benedetti Panici
Journal: Journal of Clinical Oncology (2012)

5093 Background: The aim of this study is to evaluate the efficacy, in terms of overall survival and progression free survival, and safety of adjuvant chemotherapy after neoadjuvant chemotherapy followed by radical surgery both in patients with and without node metastases. Methods: Between June 2000 to May 2007, all patients with diagnosis of locally advanced cervical cancer referred to the Division of Gynecologic Oncology of the University Campus Bio-Medico of Rome were elegible for this protocol.All enrolled patients received 3 cycles of platinum-based chemotherapy every 3 weeks according to the scheme cisplatin 100 mg/mq and paclitaxel 175 mg/mq. After neoadjuvant chemotherapy all patients with stable or progression to treatment were excluded from the protocol, all other were submitted classical radical hysterectomy and bilateral systematic pelvic lymph node dissection, and after to adjuvant treatment with 6 cycles of platinum based chemotherapy with cisplatin 100 mg/mq and paclitaxel 175 mg/mq. Results: 110 patients with local advanced cervical cancer received the treatment with neoadjuvant chemotherapy followed by radical surgery and adjuvant chemotherapy.Our study focused on clinical and operative data , in terms of overall survival and disease free survival at 5 and 3 years. 5-year OS of our series was 78% at five years and 86% at 3-years, with encouraging results also in subgroup with and without node mestastases. Conclusions: The adjuvant chemotherapy regimen after neoadjuvant chemotherapy and radical surgery rappresents a valid treatment option for patients with locally advanced cervical cancer without lymph node involvement, both in terms of overall survival than in terms of disease-free interval, the results have also confirmed the validity of this approach in lymph node metastases, with a complication rate lower than the standard radio-chemotherapy regime.
JAK2 Mutation Status in Granulocytes, Platelets and Erythrocytes Differs Between Polycythemia Vera and Essential Thrombocythemia
Authors: Kohtaro Toyama, Norifumi Tsukamoto, Akio Saito, Hirotaka Nakahashi, Yoko Hashimoto, Hiromi Koiso, Akihiko Yokohama, Hideki Uchiumi, Takayuki Saitoh, Hiroshi Handa, Hirokazu Murakami, Shuichi Miyawaki, Yoshihisa Nojima, Masamitsu Karasawa
Journal: Blood (2008)
Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation
Authors: K. Robin Yabroff, Cathy Bradley, Ya-Chen Tina Shih
Journal: Journal of Clinical Oncology (2019)

Article Tools REVIEW ARTICLES Health Services and Outcomes Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01564 Journal of Clinical Oncology - published online before print December 5, 2019 PMID: 31804869 Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation K. Robin Yabroff, PhD1xK. Robin YabroffSearch for articles by this author; Cathy Bradley, PhD2xCathy BradleySearch for articles by this author; and Ya-Chen Tina Shih, PhD3xYa-Chen Tina ShihSearch for articles by this author Show More 1Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA2University of Colorado Comprehensive Cancer Center and Colorado School of Public Health, Aurora, CO3University of Texas MD Anderson Cancer Center, Houston, TX https://doi.org/10.1200/JCO.19.01564 First Page Full Text PDF Figures and Tables © 2019 by American Society of Clinical Oncology
First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction
Authors: Fang Liu, Hongyu Zhang, Xiao Wang, Yisong Xiong, Yuanzhen Cao, Yi Su, Hai Yi, Jia Feng, Wenli Zhang, Yu Ma, Masayuki Wada, Yupo Ma
Journal: Blood (2019)
Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.
Authors: Marco Mielcarek, Barry Storer, Christoph Kahl, Brenda M. Sandmaier, David Maloney, Mike B. Maris, Rainer Storb
Journal: Blood (2005)
Prediction algorithms: pitfalls in interpreting genetic variants of autosomal dominant monogenic diabetes
Authors: Sian Ellard, Kevin Colclough, Kashyap A. Patel, Andrew T. Hattersley
Journal: Journal of Clinical Investigation (2019)

The increasing availability of DNA sequence data and access to sophisticated bioinformatic algorithms mean that an unbiased bioinformatics-based assessment of the predicted impact of a genomic variant is rapidly available.The key point of this Viewpoint article is that such bioinformatic assessments are not equivalent to an expert diagnostic interpretation and may be misleading in both research and clinical care. Prediction algorithms in genomic medicineRecently published examples involving monogenic diabetes demonstrate how pathogenicity prediction algorithms can be very inaccurate for predicting which genetic variants are likely causal of dominant monogenic disease (1-4).Here, we highlight the potential pitfalls of variant classification and how they can be avoided.A recent study used a bioinformatic algorithm to identify 88 "likely pathogenic" monogenic diabetes variants in 80 individuals (8.6%) from a cohort of 1019 individuals with type 1 diabetes for 50 or more years (4).Application of the widely used American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) standards and guidelines (5) classifies only nine of these 88 variants as likely pathogenic or pathogenic variants that would be reported by our clinical diagnostic laboratory as likely causative of the patients' diabetes.This is not an isolated occurrence; other published research studies with an overreliance on in silico prediction tools have reported high levels (~90%) of false positive "likely pathogenic" monogenic diabetes variants (1-3).We have seen clinical diagnostic reports from laboratories in eight coun- Conflict of interest:The authors have declared that no conflict of interest exists.
Strategic Need for Large Prospective Studies in Different Populations
Authors: Zhengming Chen, Jonathan Emberson, Rory Collins
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immune Response to the 23-Valent Polysaccharide Pneumococcal Vaccine (PPV23) after the 7-Valent Conjugate Vaccine (PCV7) in Allogeneic Stem Cell Transplant (SCT) Recipients: Results of the EBMT IDWP01 Trial
Authors: Catherine Cordonnier, Myriam Labopin, Virginie Chesnel, Patricia Ribaud, Rafael De La Camara, Rodrigo Martino, Andrew Ullmann, Terttu Parkkali, Anna Locasciulli, Karima Yakouben, Karlis Pauksens, Hermann Einsele, Dietger Niederwieser, Jane Apperley, Per T. Ljungman
Journal: Blood (2008)
Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer
Authors: Elizabeth M. Cespedes Feliciano, Wendy Y. Chen, Valerie Lee, Kathleen B. Albers, Carla M. Prado, Stacey Alexeeff, Jingjie Xiao, Shlomit S. Shachar, Bette J. Caan
Journal: JAMA Oncology (2019)

Although most chemotherapies are dosed on body surface area or weight, body composition (ie, the amount and distribution of muscle and adipose tissues) is thought to be associated with chemotherapy tolerance and adherence.To evaluate whether body composition is associated with relative dose intensity (RDI) on anthracycline and taxane-based chemotherapy or hematologic toxic effects and whether lower RDI mediates the association of adiposity with mortality.An observational cohort study with prospectively collected electronic medical record data was conducted at Kaiser Permanente Northern California, a multicenter, community oncology setting within an integrated health care delivery system. Participants included 1395 patients with nonmetastatic breast cancer diagnosed between January 1, 2005, and December 31, 2013, and treated with anthracycline and taxane-based chemotherapy. Data analysis was performed between February 25 and September 4, 2019.Intramuscular, visceral, and subcutaneous adiposity as well as skeletal muscle were evaluated from clinically acquired computed tomographic scans at diagnosis.The primary outcome was low RDI (<0.85), which is the ratio of delivered to planned chemotherapy dose, derived from infusion records; in addition, hematologic toxic effects were defined based on laboratory test values. To evaluate associations with overall and breast cancer-specific mortality, logistic regression models adjusted for age and body surface area were fit as well as Cox proportional hazards models adjusted for age, race/ethnicity, adiposity, Charlson comorbidity index score, and tumor stage and subtype. The mediation proportion was computed using the difference method.The mean (SD) age at diagnosis of the 1395 women included in the study was 52.8 (10.2) years. Greater visceral (odds ratio [OR], 1.19; 95% CI, 1.02-1.39 per SD) and intramuscular (OR, 1.16; 95% CI, 1.01-1.34 per SD) adiposity were associated with increased odds of RDI less than 0.85. Greater muscle mass was associated with a decreased odds of hematologic toxic effects (OR, 0.84; 95% CI, 0.71-0.98 per SD). Relative dose intensity less than 0.85 was associated with a 30% increased risk of death (hazard ratio, 1.30; 95% CI, 1.02-1.65). Lower RDI partially explained the association of adiposity with breast cancer-specific mortality (mediation proportion, 0.20; 95% CI, 0.05-0.55).Excess adiposity, presenting as larger visceral or intramuscular adiposity, was associated with lower RDI. Lower RDI partially mediated the association of adiposity with worse breast cancer-specific survival. Body composition may help to identify patients likely to experience toxic effects and subsequent dose delays or reductions, which could compromise chemotherapeutic efficacy.
Hodgkin Lymphoma (HL) in Tunisia Results of a 5 Year Prospective Multicenter Trial in 251 Pts
Authors: R. Ben Lakhal, S. Hdiji, M. A Laatiri, S. Ladeb, R. Jeddi, L. Aissaoui, R. Ben Amor, F. Msadek, H. Frikha, N. Toumi, J. Daoud, N. Bouaouina, Z. Belhadj Ali, H. Ben Abid, M. Frikha, M. Elloumi, A. Khelif, B. Meddeb, Pierre Fenaux
Journal: Blood (2008)
Regulation of Tumor Initiation by the Mitochondrial Pyruvate Carrier
Authors: Claire L. Bensard, Dona R. Wisidagama, Kristofor A. Olson, Jordan A. Berg, Nathan M. Krah, John C. Schell, Sara M. Nowinski, Sarah Fogarty, Alex J. Bott, Peng Wei, Katja K. Dove, Jason M. Tanner, Vanja Panic, Ahmad Cluntun, Sandra Lettlova, Christian S. Earl, David F. Namnath, Karina Vázquez-Arreguín, Claudio J. Villanueva, Dean Tantin, L. Charles Murtaugh, Kimberley J. Evason, Gregory S. Ducker, Carl S. Thummel, Jared Rutter
Journal: Cell Metabolism (2019)
On the Origin of Lung Cancers
Authors: Adam Pennycuick, Sam M. Janes
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

On the Origin of Lung CancersIt is widely accepted that early diagnosis is crucial for improving outcomes in lung cancer, which is currently the leading cause of cancer-related death in the United States (1).Computed tomography screening studies have demonstrated remarkable mortality benefits through a stage shift at diagnosis (2).Yet, our understanding of early carcinogenesis remains poor, and the precise mechanisms by which a smoke-exposed lung cell undergoes malignant transformation are mysterious.Studies of advanced lung cancers have shown highly complex genomic landscapes beset with thousands of somatic mutations and copy number aberrations (3, 4).Moreover, individual cancers are highly heterogeneous within themselves (5).This complexity makes the identification of biomarkers and effective therapeutic targets extremely challenging; inhibitors of EGFR and ALK are effective, but although response rates are reasonable, relapse is universal (6).To detect and treat cancer earlier, we must understand its origins.Before lung adenocarcinoma (ADC) becomes manifest, early histological changes occur in the lung, beginning with ADC in situ (AIS) followed by minimally invasive ADC (MIA).In a study presented in this issue of the Journal, Qian and colleagues (pp.697-706) performed genomic sequencing on 21 AISs, 27 MIAs, and 54 invasive ADCs obtained from lung resections to identify early changes leading to cancerous transformation (7).Interestingly, these early lesions already displayed extensive molecular changes.Although the mutation burden was higher in ADCs, driver mutations and copy number changes were identified in AISs and MIAs, and heterogeneity was observed even at these early stages of carcinogenesis.As the authors state, "AIS, although preinvasive, has the full genomic alteration profile displayed in invasive cancer"-a finding that is mirrored in preinvasive studies of squamous lung cancers (8).The authors applied a number of methods to tease out biological signals specific to early disease.They identified 21 genes that were significantly mutated across histologies, several of which showed a trend toward more mutations in more advanced disease.Copy number losses were more common in AISs/MIAs, and gains were more common in ADCs.An analysis of mutational signatures demonstrated enrichment of a DNA mismatch-repair-associated signature.This was a surprising finding, as ADCs tend to be dominated by smoking-related signature 4 mutations (9) (although this finding may have been skewed by the targeted sequencing approach used).Again, however, it was not possible to differentiate histological stages by their mutational signatures.Perhaps most intriguingly, the authors used a computational approach called Pipeline for Cancer Inference to compare mutations across successive histological subtypes in an effort to identify causative
Innate Immune Response to Cytoplasmic DNA: Mechanisms and Diseases
Authors: Ming-Ming Hu, Hong-Bing Shu
Journal: Annual Review of Immunology (2019)

DNA has been known to be a potent immune stimulus for more than half a century. However, the underlying molecular mechanisms of DNA-triggered immune response have remained elusive until recent years. Cyclic GMP-AMP synthase (cGAS) is a major cytoplasmic DNA sensor in various types of cells that detect either invaded foreign DNA or aberrantly located self-DNA. Upon sensing of DNA, cGAS catalyzes the formation of cyclic GMP-AMP (cGAMP), which in turn activates the ER-localized adaptor protein MITA (also named STING) to elicit the innate immune response. The cGAS-MITA axis not only plays a central role in host defense against pathogen-derived DNA but also acts as a cellular stress response pathway by sensing aberrantly located self-DNA, which is linked to the pathogenesis of various human diseases. In this review, we summarize the spatial and temporal mechanisms of host defense to cytoplasmic DNA mediated by the cGAS-MITA axis and discuss the association of malfunctions of this axis with autoimmune and other diseases.
Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer
Authors: Qi Cao, Zhengshuai Song, Hailong Ruan, Cheng Wang, Xiong Yang, Lin Bao, Keshan Wang, Gong Cheng, TianBo Xu, Wen Xiao, Zhiyong Xiong, Di Liu, Ming Yang, Diwei Zhou, Hongmei Yang, Ke Chen, Xiaoping Zhang
Journal: Clinical Cancer Research (2019)

Emerging evidence indicates that castration-resistant prostate cancer (CRPC) is often driven by constitutively active androgen receptor (AR) or its V7 splice variant (AR-V7) and commonly becomes resistant to endocrine therapy. The aim of this work is to evaluate the function of a kinesin protein, KIF4A, in regulating AR/AR-V7 in prostate cancer endocrine therapy resistance.We examined KIF4A expression in clinical prostate cancer specimens by IHC. Regulated pathways were investigated by qRT-PCR, immunoblot analysis, immunoprecipitation, and luciferase reporter and chromatin immunoprecipitation (ChIP) assays. A series of functional analyses were conducted in cell lines and xenograft models.Examination of the KIF4A protein and mRNA levels in patients with prostate cancer showed that increased expression of KIF4A was positively correlated with androgen receptor (AR) levels. Patients with lower tumor KIF4A expression had improved overall survival and disease-free survival. Mechanistically, KIF4A and AR form an auto-regulatory positive feedback loop in prostate cancer: KIF4A binds AR and AR-V7 and prevents CHIP-mediated AR and AR-V7 degradation; AR binds the promoter region of KIF4A and activates its transcription. KIF4A promotes castration-sensitive and castration-resistant prostate cancer cell growth through AR- and AR-V7-dependent signaling. Furthermore, KIF4A expression is upregulated in enzalutamide-resistant prostate cancer cells, and KIF4A knockdown effectively reverses enzalutamide resistance and enhances the sensitivity of CRPC cells to endocrine therapy.These findings indicate that KIF4A plays an important role in the progression of CRPC and serves as a crucial determinant of the resistance of CRPC to endocrine therapy.
Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.
Authors: Andreas Hochhaus, Philipp Erben, Susan Branford, Jerald Radich, D.W. Kim, Giovanni Martinelli, Giuseppe Saglio, Martin C. Mueller, Jana Hoffmann, Francesca Palandri, Simona Soverini, Timothy Hughes, Yaping Shou, Aaron Weitzman, Michele Baccarani
Journal: Blood (2006)
Retrospective Comparison of Using or Not Using Donor Lymphocyte Transfusion in the Treatment of Hematological Relapse after Allogeneic Stem Cell Transplantation in 489 Adults with Acute Myeloid Leukemia.
Authors: Christoph Schmid, Myriam Labopin, Juergen Finke, Gerhard Ehninger, Olle Ringden, Dietger Niederwieser, Ioanna Sakellari, Alvaro Urbano-Ispizua, Tapani Ruutu, Gunham Gurman, Richard E. Clarke, Norbert Gorin, Emmanuelle Polge, Loic Fouillard, Francesco Frassoni, Hans-Jochem Kolb
Journal: Blood (2004)
The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study
Authors: Li Yang, Ligen Liu, Limin Zhao, Yingting Lu, Jing Zhang, Lihua Sun
Journal: Blood (2019)